Clinical characteristics of the study population
| All patients (n=115) | Men (n=76) | Women (n=39) | P value* | |
| Age at diagnosis, years | 45.8±13.7 | 43.2±12.3 | 50.8±15.1 | 0.009 |
| Probands | 71 (62%) | 50 (66%) | 21 (54%) | 0.230 |
| Family history | 93 (81%) | 58 (76%) | 35 (90%) | 0.130 |
| Diabetes | 9 (8%) | 7 (9%) | 2 (5%) | 0.716 |
| Hypertension | 15 (13%) | 7 (9%) | 8 (21%) | 0.142 |
| NYHA III–IV | 56 (49%) | 41 (54%) | 15 (38%) | 0.167 |
| LVEF at diagnosis, % | 28.3±12.7 | 27.0±12.1 | 30.8±13.6 | 0.152 |
| LVEDD at diagnosis, mm/m2 | 31.7±4.6 | 31.2±4.4 | 32.5±5.0 | 0.197 |
| ACE-inhibitor/ARB | 94 (82%) | 63 (83%) | 31 (79%) | 0.607 |
| Beta blocker | 82 (71%) | 55 (%) | 27 (69%) | 0.665 |
| Diuretic | 60 (52%) | 42 (55%) | 18 (46%) | 0.331 |
| Aldosterone antagonist | 50 (43%) | 33 (43%) | 17 (44%) | 0.999 |
| ICD | 22 (19%) | 17 (22%) | 5 (13%) | 0.317 |
| CRT-P | 2 (2%) | 0 (0%) | 2 (5%) | 0.113 |
| CRT-D | 9 (8%) | 7 (9%) | 2 (5%) | 0.716 |
| AV-block† | 29 (29%) | 17 (27%) | 12 (32%) | 0.658 |
| Left bundle branch block‡ | 21 (20%) | 15 (23%) | 6 (16%) | 0.456 |
Bold text indicates a statistically significant difference between the sexes.
*P values are based on comparisons between men and women.
†On latest available ECG without pace rhythm or AF (n=100).
‡On latest available ECG without pace rhythm (n=104).
AF, atrial fibrillation; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronisation therapy defibrillator; CRT-P, cardiac resynchronisation therapy pacemaker; ICD, implantable cardioverter-defibrillator; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional class.